Based on the above finding, vitamin C and D supplementation is recommended in AML patients harboring NPM1 mutations for improving their OS and in all AML patients for lowering the rates of grade 3 and 4 adverse events [143]. The gene discussed is NPM1; the disease is acute myeloid leukemia.